Study Comparing Metformin and Febuxostat in Treating Gout in Obese Adults Without Diabetes

What this Trial Is About

Gout is a systemic condition caused by the buildup of monosodium urate crystals in tissues, especially around joints, resulting from high serum uric acid levels above 6.8 mgdl. This research aims to compare the effects of two drugs, Metformin and Febuxostat, on obese patients with gout who do not have diabetes. The study is a phase 2 randomized trial assessing how these treatments impact gout management by lowering serum uric acid levels. Participants will be randomly assigned to one of two groups. One group will receive Febuxostat 80 mg daily, a drug that inhibits uric acid production, for six months. The other group will take Metformin 1000 mg daily, a medication usually used for diabetes but being studied here for its potential effects on gout, also for six months. Both treatments are being compared under double-blind conditions to evaluate their effects on gouty obese non-diabetic patients. During the study, participants will have their serum uric acid levels measured, with the primary outcome being the change at three months. The study will monitor biochemical and clinical changes over the six months of treatment. Patients will be assessed to see how these medications influence gout symptoms and uric acid levels, with safety and effectiveness carefully observed throughout the trial period.

Comparative Clinical and Biochemical Study Evaluating the Effectiveness of Metformin Versus Febuxostat on Gouty Obese Non-Diabetic Patients